FDA 블랙박스 경고: BUMETANIDE
FDA 블랙박스 경고 — BUMETANIDE (Bumetanide)
2026-03-11
블랙박스 경고
Bumetanide (BUMETANIDE) — AvPAK
WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ).
약물 상호작용
Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) . Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. Drugs with Nephrotoxic Potential There has been no experience with the concurrent use of bumetanide with drugs known to have a nephrotoxic potential. Therefore, the simultaneous administration of these dru
주의사항
WARNINGS Volume and Electrolyte Depletion The dose of bumetanide should be adjusted to the patient's need. Excessive doses or too frequent administration can lead to profound water loss, electrolyte depletion, dehydration, reduction in blood volume and circulatory collapse with the possibility of vascular thrombosis and embolism, particularly in elderly patients. Hypokalemia Hypokalemia can occur as a consequence of bumetanide administration. Prevention of hypokalemia requires particular attenti
이 정보는 FDA 공공 데이터를 기반으로 하며, 의사/약사의 전문적 판단을 대체하지 않습니다.
복용 중인 약이 해당되는지 확인하세요
상호작용 체크하러 가기이 정보는 공식 안전 정보를 기반으로 하며, 의사/약사의 전문적 판단을 대체하지 않습니다.